American Society of Hematology

American Society of Hematology

December 6–9, 2025 | Orlando, United States

American Society of Hematology

  • Date: December 6–9, 2025

  • Exhibit location:

    Orange County Convention Center
    9800 International Dr.
    Orlando, FL 32819

  • Booth:

    Booth #409

  • Saturday, Dec 6: 11 AM to 5 PM EST
    Sunday, Dec 7: 10 AM to 5 PM EST
    Monday, Dec 8: 10 AM to 2 PM EST

location
absolute

Key Data Presentations

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

ASH 2025 FL Zanubrutinib

Pier Luigi Zinzani

FIND OUT MORE

Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1/2 study

ASH 2025 MCL BGB-11417, Sonrotoclax

Michael Wang

FIND OUT MORE

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

ASH 2025 CLL/SLL

Jennifer R. Brown

FIND OUT MORE

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

ASH 2025 CLL/SLL Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)

ASH 2025 CLL/SLL Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D

ASH 2025 CLL/SLL Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

ASH 2025 CLL/SLL BGB-16673

Meghan C. Thompson

FIND OUT MORE

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

ASH 2025 CLL/SLL BGB-11417, Sonrotoclax, Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Number needed to treat to avoid progression or death: Zanubrutinib vs other covalent Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia

ASH 2025 CLL Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

ASH 2025 CLL Zanubrutinib

Inhye E. Ahn

FIND OUT MORE

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

ASH 2025 CLL Zanubrutinib

Aryan Ayati

FIND OUT MORE

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

ASH 2025 DLBCL Zanubrutinib

Li Wang

FIND OUT MORE

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

ASH 2025 B-cell malignancies Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring

ASH 2025 CLL

Gurjyot Doshi

FIND OUT MORE

Refine results

Congress + Year down arrow
ASH 2025 (36)
Disease State down arrow
B-cell malignancies (2) B-cell NHL (1) CLL (12) CLL/SLL (12) DLBCL (1) FL (1) MCL (3) MM (1) NHL (1) Treatment Naive CLL/SLL (1) WM (1) SHOW ALL
Molecule down arrow
Zanubrutinib (14) Sonrotoclax (8) BGB-11417 (7) BGB-16673 (6) BGB-21447 (1) SHOW ALL
Type down arrow
Oral (7) Poster (28)

Loading results...

Loading...

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed